* Primary objective is to assess the safety of MG1111 until Day 42 using as 2nd vaccination * Secondary objective to assess the immunogenicity and safety of MG1111 using as 2nd vaccination
Healthy children between 4 and 6 years of age as of the date of written consent
Subjects who have a history of 1st Varicella vaccination at least 3 years ago from the administration of investigational product
Subjects or parent/legal representative willing to provide written informed consent and able to comply with the study requirements
Negative history of Varicella infection
Subjects with a history of exposure to varicella through contact with a varicella patient at home, school, or childcare facility within 4 weeks before the administration of investigational drug
Subjects who have a history 2 times or more of varicella vaccine injections
Subjects who had an acute febrile (at least 38.0 ℃) episode at some time during the 72 hours before the administration of investigational product
Subjects who had any suspected allergy symptoms including systemic rash during the 72 hours before the administration of investigational product